Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.
[hodgkin lymphoma, classical]
In
recent
years
,
research
has
increasingly
focused
on
the
microenvironment
of
classical
Hodgkin
lymphoma
(
CHL
)
as
a
predictor
of
treatment
outcome
.
The
focus
of
this
study
was
to
assess
the
interobserver
reproducibility
in
interpreting
macrophage-associated
immunohistochemistry
(
IHC
)
for
CD
68
and
CD
163
in
a
retrospective
cohort
of
88
patients
with
CHL
.
S
taining
results
were
correlated
with
clinical
outcome
in
all
patients
and
those
with
a
high
international
prognostic
score
(
IPS
)
.
The
intraclass
correlation
(
ICC
)
for
the
five
hematopathologists
interpreting
the
IHC
was
stronger
for
CD
163
(
0
.
70
)
than
for
CD
68
(
0
.
50
)
.
Using
a
cutoff
of
25
%
mean
macrophage
reactivity
and
including
all
patients
,
a
statistically
significant
difference
in
overall
survival
(
OS
)
was
seen
only
for
CD
163
(
P
=
.
0006
)
and
not
for
CD
68
(
P
=
.
414
)
.
Patients
with
a
mean
CD
163
reactivity
of
25
%
or
more
had
a
median
OS
of
71
months
vs
101
months
for
patients
with
less
than
25
%
reactivity
.
CD
163
retained
statistical
significance
in
multivariate
analysis
.
In
patients
with
advanced
-
stage
CHL
with
high
IPS
,
OS
was
also
significantly
worse
for
those
with
a
mean
CD
163
reactivity
of
25
%
or
higher
.
Our
study
confirms
previous
reports
of
a
prognostic
role
of
tumor
-infiltrating
macrophages
in
CHL
,
but
only
for
CD
163
.
Although
most
of
the
literature
supports
an
increasing
role
of
macrophage
IHC
as
a
predictor
of
clinical
outcome
,
successful
clinical
translation
will
require
a
standardized
method
and
reporting
system
.
